Viscosupplementation Market Size, Share, Opportunities, And Trends By Dosage (Single Injection, Three Injection, Five Injection), By Application (Knee Osteoarthritis, Hip Osteoarthritis, Shoulder Osteoarthritis, Others), By End-user (Hospitals, Ambulatory Surgical Centers, Orthopedic Clinics), And By Geography - Forecasts From 2024 To 2029

The viscosupplementation market is anticipated to grow significantly over the forecast period.

One typical medical method for treating osteoarthritis, especially in the knee joint, is viscosupplementation. To increase lubrication and lessen discomfort and inflammation, hyaluronic acid (HA), a viscous fluid, is injected into the joint area. The synovial fluid contains hyaluronic acid, a naturally occurring chemical that lubricates and cushions joints. Increased friction and discomfort result from the natural HA in the joint being thinner and less effective due to osteoarthritis. The goal of viscosupplementation is to improve joint function and lessen discomfort by returning the synovial fluid's viscosity and flexibility. This treatment is regarded as a non-surgical approach to treating osteoarthritis symptoms and is usually administered as a series of injections spread out over a few weeks.

Osteoarthritis is becoming more common, the need for less intrusive treatments is growing, and the aging population is driving major growth in the viscosupplementation industry. Viscosupplements are injected into joints to lubricate them and reduce pain related to osteoarthritis. They are made of hyaluronic acid. The market is developing due to technological developments in viscosupplementation techniques and growing uses in knee, hip, and shoulder joints. The market is expected to increase at a rapid rate due in part to advantageous reimbursement policies and rising public awareness of the advantages of viscosupplementation. Generally, as the demand for efficient osteoarthritis management options rises, the viscosupplementation market is expected to continue growing.

Market Drivers

• The increasing prevalence of osteoarthritis is expected to drive the viscosupplementation market.

The prevalence of cardiac arrhythmias is increasing worldwide, owing to factors such as aging populations, sedentary lifestyles, and rising rates of cardiovascular disease. Cardiac arrhythmias refer to a variety of diseases, including atrial fibrillation, ventricular tachycardia, and bradyarrhythmias, all of which can have a major impact on patient health and quality of life. As the prevalence of risk factors such as obesity, hypertension, and diabetes rises, so does the impact of cardiac arrhythmias on global healthcare systems. This development highlights the growing need for effective diagnostic and therapeutic options to address the rising prevalence of cardiac arrhythmias while lowering associated morbidity and mortality rates.

According to NCBI in 2023, The most prevalent type of arthritis identified is knee osteoarthritis, and as life expectancy and obesity increase, so too will the incidence of this condition. Roughly 10% of men and 13% of women 60 years of age and older have symptomatic osteoarthritis in their knees, according to various sources. The frequency increases to 40% among people over the age of 70. Men are also less likely than women to have osteoarthritis in their knees. Remarkably, not all individuals exhibiting radiographic signs of osteoarthritis in the knee will experience symptoms. According to one study, only 15% of patients with knee OA identified on radiographs also had symptoms. When age is not taken into account, the annual incidence of symptomatic knee osteoarthritis is about 240 cases per 100,000 persons.

• Technological advancement in viscosupplementation is expected to boost the market.

Treatment choices for patients with osteoarthritis have been changed by technological breakthroughs in the viscosupplementation business. The safety and efficacy of viscosupplementation therapy have been greatly increased by innovations like better delivery devices, optimized formulations, and better injection techniques. Modern biomaterials and cross-linking methods guarantee the long-term strength and effectiveness of materials injected into joints. In addition, the advancement of ultrasound and fluoroscopy-guided injection techniques allows for accurate administration, improving the results of treatment. The incorporation of digital health technologies enables the implementation of customized treatment regimens and remote monitoring. These developments broaden the usefulness and acceptability of viscosupplementation therapy, which not only enhances patient experience but also propels market growth.

According to NCBI, One prevalent hallmark of inflammatory OA is synovitis, which has been detected in many patients at different stages of the illness by technological advancements in imaging technologies such as MRI and ultrasound. Numerous factors, such as abnormal mechanical pressures, metabolic syndrome, aging, and pieces of extracellular matrix (ECM) or crystals in the cartilage, may cause the release of these mediators from different types of responsive joint tissue cells. Numerous new review studies discuss how the innate immune system's cells and elements are the primary causes of the inflammatory processes associated with OA. Although glucocorticoids and non-steroidal anti-inflammatory medications (NSAIDs) are frequently used to treat osteoarthritis (OA), their efficacy is only limited, and their long-term use can have substantial side effects

• The aging population is a significant driver for the market.

The market for viscosupplementation is significantly influenced by the aging population since osteoarthritis, which is characterized by stiffness and pain in the joints, is more common in older people. Osteoarthritis cases are becoming more common due to the world's demographic shift toward an aging population, especially in affluent nations. The natural lubricant in people's joints decreases with age, causing discomfort and limited movement. By adding more synovial fluid to joints, viscosupplementation offers an efficient therapeutic approach that reduces discomfort and enhances joint function. Thus, the market for viscosupplementation is expanding as a result of the aging population's growing need.

Additionally, WHO 2023 reported that osteoarthritis affected around 528 million individuals globally in 2019—a 113% rise since 1990. Over 55-year-olds make up about 73% of those with osteoarthritis, and 60% of those affected are female. The knee is the most commonly affected joint, with a prevalence of 365 million, followed by the hip and the hand. Rehabilitation could be beneficial for 344 million individuals who suffer from mild to severe osteoarthritis. Globally, osteoarthritis prevalence is predicted to rise because of aging populations, rising rates of obesity, and an increase in injuries. Osteoarthritis is an inevitable side effect of becoming older

Asia Pacific region is expected to grow significantly.

In the Asia-Pacific area, viscosupplementation—a therapy that involves injecting hyaluronic acid into joints to relieve osteoarthritis pain—has grown rapidly. This growth has been driven by elements including an aging population, an increase in osteoarthritis cases, and growing knowledge of non-surgical treatment alternatives. Because of their substantial older populations and sophisticated healthcare systems, nations like China, Japan, and South Korea have seen a strong uptake. Furthermore, the spike in demand has been attributed to both technology developments and pharmaceutical corporations' aggressive marketing campaigns. The market for viscosupplementation in the Asia-Pacific region is expected to rise further due to changing patient preferences and increased accessibility to healthcare services.

In 2021, Based on the encouraging pre-clinical outcomes of LG00034053, a novel medication candidate for the treatment of osteoarthritis, LG Chem declared on the 4th that the company has been granted approval by the Korean Ministry of Food and Drug Safety for the Phase 1b/2 clinical trials.LG Chem aims to expedite the creation of novel medications by creating clinical trials that connect Phases 1 and 2. With the help of this approval, LG Chem will carry out studies at Samsung Medical Center to determine the best dose for patients with mild to moderate knee osteoarthritis (K&L2-3) by assessing factors like safety and tolerability, pharmacokinetics (the process of drug absorption, distribution, metabolism, and excretion), and effectiveness.

Market Restraints

• Availability of alternative treatments and competition from other therapeutic approaches constraint the market

Viscosupplementation, a treatment for osteoarthritis, offers pain reduction and improved joint function despite its competition with oral drugs, physical therapy, and surgical procedures. However, patient variability in efficiency raises questions about its long-term effects and usefulness. Access to and acceptance of viscosupplementation may be limited by uneven insurance coverage and payment regulations. Further research, instruction, and cooperation are needed to maximize its application.

Market Developments

• May 2022- Fidia Farmaceutici S.p.A. launches its cutting-edge range in Spain in May 2022, utilizing hyaluronic acid's capacity for regeneration. During a scientific seminar on its novel ACP (Auto-Crosslinked Polymer) technology, Fidia Farmaceutici S.p.A. showcased its Aesthetic Care portfolio at the 20th Aesthetic & Anti-aging Medicine World Congress 2022 (AMWC) in Monte Carlo. In Spain, the business has introduced the whole Hyal System and Hy-Tissue product line. This has aided the business in showcasing its hyaluronic acid research.
• April 2022- To develop and commercialize TissueGene-C low dose (TG-C LD), a non-surgical experimental therapy provided as a single intra-articular injection, to treat knee osteoarthritis, Juniper Biologics and Kolon Life Sciences inked a licensing agreement in April 2022. As part of the licensing agreement, Juniper will research and promote gene therapy to hospitals and physicians throughout Africa, the Middle East, and Asia-Pacific.

Segmentation

• By Dosage
  • Single Injection
  • Three Injection
  • Five Injection
• By Application
  • Knee Osteoarthritis
  • Hip Osteoarthritis
  • Shoulder Osteoarthritis
  • Others
• By End-user
  • Hospitals
  • Ambulatory Surgical Centers
  • Orthopedic Clinics
• By Geography
  • North America
    • USA
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Taiwan
    • Thailand
    • Indonesia
    • Others

1. INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline

1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY  

2.1. Research Design

2.2. Research Processes

3. EXECUTIVE SUMMARY

3.1. Key Findings

3.2. Analyst View

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Forces Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

4.5. Analyst View

5. VISCOSUPPLEMENTATION MARKET BY DOSAGE

5.1. Introduction

5.2. Single Injection

5.2.1. Market Opportunities and Trends

5.2.2. Growth Prospects

5.3. Three Injection

5.3.1. Market Opportunities and Trends

5.3.2. Growth Prospects

5.4. Five Injection 

5.4.1. Market Opportunities and Trends

5.4.2. Growth Prospects

6. VISCOSUPPLEMENTATION MARKET BY APPLICATION

6.1. Introduction

6.2. Knee Osteoarthritis

6.2.1. Market Opportunities and Trends

6.2.2. Growth Prospects

6.3. Hip Osteoarthritis

6.3.1. Market Opportunities and Trends

6.3.2. Growth Prospects

6.4. Shoulder Osteoarthritis

6.4.1. Market Opportunities and Trends

6.4.2. Growth Prospects

6.5. Others

6.5.1. Market Opportunities and Trends

6.5.2. Growth Prospects

7. VISCOSUPPLEMENTATION MARKET BY END-USER

7.1. Introduction

7.2. Hospitals

7.2.1. Market Opportunities and Trends

7.2.2. Growth Prospects

7.3. Ambulatory Surgical Centers

7.3.1. Market Opportunities and Trends

7.3.2. Growth Prospects

7.4. Orthopedic Clinics

7.4.1. Market Opportunities and Trends

7.4.2. Growth Prospects

8. VISCOSUPPLEMENTATION MARKET BY GEOGRAPHY

8.1. Introduction

8.2. North America

8.2.1. By Dosage

8.2.2. By Application

8.2.3. By End User

8.2.4. By Country

8.2.4.1. United States

8.2.4.1.1. Market Opportunities and Trends

8.2.4.1.2. Growth Prospects

8.2.4.2. Canada

8.2.4.2.1. Market Opportunities and Trends

8.2.4.2.2. Growth Prospects

8.2.4.3. Mexico

8.2.4.3.1. Market Opportunities and Trends

8.2.4.3.2. Growth Prospects

8.3. South America

8.3.1. By Dosage

8.3.2. By Application

8.3.3. By End User

8.3.4. By Country 

8.3.4.1. Brazil

8.3.4.1.1. Market Opportunities and Trends

8.3.4.1.2. Growth Prospects

8.3.4.2. Argentina

8.3.4.2.1. Market Opportunities and Trends

8.3.4.2.2. Growth Prospects

8.3.4.3. Others

8.3.4.3.1. Market Opportunities and Trends

8.3.4.3.2. Growth Prospects

8.4. Europe

8.4.1. By Dosage

8.4.2. By Application

8.4.3. By End User

8.4.4. By Country

8.4.4.1. United Kingdom

8.4.4.1.1. Market Opportunities and Trends

8.4.4.1.2. Growth Prospects

8.4.4.2. Germany

8.4.4.2.1. Market Opportunities and Trends

8.4.4.2.2. Growth Prospects

8.4.4.3. France

8.4.4.3.1. Market Opportunities and Trends

8.4.4.3.2. Growth Prospects

8.4.4.4. Italy

8.4.4.4.1. Market Opportunities and Trends

8.4.4.4.2. Growth Prospects

8.4.4.5. Spain

8.4.4.5.1. Market Opportunities and Trends

8.4.4.5.2. Growth Prospects

8.4.4.6. Others

8.4.4.6.1. Market Opportunities and Trends

8.4.4.6.2. Growth Prospects

8.5. Middle East and Africa

8.5.1. By Dosage

8.5.2. By Application

8.5.3. By End User

8.5.4. By Country

8.5.4.1. Saudi Arabia

8.5.4.1.1. Market Opportunities and Trends

8.5.4.1.2. Growth Prospects

8.5.4.2. UAE

8.5.4.2.1. Market Opportunities and Trends

8.5.4.2.2. Growth Prospects

8.5.4.3. Others

8.5.4.3.1. Market Opportunities and Trends

8.5.4.3.2. Growth Prospects

8.6. Asia Pacific

8.6.1. By Dosage

8.6.2. By Application

8.6.3. By End User

8.6.4. By Country

8.6.4.1. Japan

8.6.4.1.1. Market Opportunities and Trends

8.6.4.1.2. Growth Prospects

8.6.4.2. China

8.6.4.2.1. Market Opportunities and Trends

8.6.4.2.2. Growth Prospects

8.6.4.3. India

8.6.4.3.1. Market Opportunities and Trends

8.6.4.3.2. Growth Prospects

8.6.4.4. South Korea

8.6.4.4.1. Market Opportunities and Trends

8.6.4.4.2. Growth Prospects

8.6.4.5. Taiwan

8.6.4.5.1. Market Opportunities and Trends

8.6.4.5.2. Growth Prospects

8.6.4.6. Thailand

8.6.4.6.1. Market Opportunities and Trends

8.6.4.6.2. Growth Prospects

8.6.4.7. Indonesia

8.6.4.7.1. Market Opportunities and Trends

8.6.4.7.2. Growth Prospects

8.6.4.8. Others

8.6.4.8.1. Market Opportunities and Trends

8.6.4.8.2. Growth Prospects

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Market Share Analysis

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Competitive Dashboard

10. COMPANY PROFILES

10.1. Sanofi S.A.

10.2. Zimmer Biomet Holdings Inc.

10.3. Bioventus LLC

10.4. Anika Therapeutics Inc.

10.5. Fidia Farmaceutici S.p.A.

10.6. Chugai Pharmaceuticals Co., Ltd

10.7. Ferring Pharmaceuticals

10.8. OrthogenRx Inc. 

10.9. Wellchem Pharmaceuticals Pte Ltd. 

Sanofi S.A.

Zimmer Biomet Holdings Inc.

Bioventus LLC

Anika Therapeutics Inc.

Fidia Farmaceutici S.p.A.

Chugai Pharmaceuticals Co., Ltd

Ferring Pharmaceuticals

OrthogenRx Inc. 

Wellchem Pharmaceuticals Pte Ltd.